Aspirin may reduce elevated risk of cancer caused by obesity
the ONA take:
Taking aspirin regularly can negate the increased the risk for developing colorectal cancer in patients with Lynch syndrome, according to a new study published online ahead of print in the Journal of Clinical Oncology has shown.
"This is important for people with Lynch Syndrome but affects the rest of us too. Lots of people struggle with their weight and this suggests the extra cancer risk can be cancelled by taking an aspirin," Professor Sir John Blum, professor of Clinical Genetics at Newcastle University in Leeds, UK, said.
For the study, researchers enrolled 937 patients with Lynch syndrome and randomly assigned them to receive aspirin 600 mg per day or placebo, plus resistant starch 30 g per day or placebo. Results showed that during a median follow-up of 55.7 months, the risk of colorectal cancer was nearly 2.5 times higher for overweight participants than for underweight and normal-weight participants.
Obese patients had a 1.77 times increased risk of Lynch syndrome-related cancer compared with normal-weight participants.
The findings suggest that overweight patients with Lynch syndrome are likely to benefit from obesity prevention and/or regular aspirin.
Taking aspirin regularly can negate the increased the risk for developing colorectal cancer in patients with Lynch syndrome.
- Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia
- Ruxolitinib: A Targeted Treatment Option for Patients with Polycythemia Vera
- Incontinence Affects QOL for Survivors of Gynecologic Cancers
- Adding Bevacizumab to Adjuvant Capecitabine Not Effective for mCRC
- ASCO, ASTRO Issue Guideline Update for Postmastectomy RT
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- Ruxolitinib Effective as Long-term Treatment Option for Polycythemia Vera
- Definitive IMRT Associated With Shorter Feeding Tube Placement Duration in HNC
- SBRT Improves Overall and Disease-Specific Survival in Stage I NSCLC
- Patients Receiving RT in APBI Facilities Despite Eligibility for Observation
- Prolonged Imatinib Therapy Improves Likelihood of Deeper Molecular Response
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|